ReviewMolecular biotechnology2005
Tumor necrosis factor as a pharmacological target.
Review in Molecular biotechnology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 45 citations in OpenAlex.
- Aminoacyl-tRNA synthetases, therapeutic targets for infectious diseases.Biochemical pharmacology · 2018Review
- miR-29a up-regulation in AR42J cells contributes to apoptosis via targeting TNFRSF1A gene.World journal of gastroenterology · 2016Article
- Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.International journal of cell biology · 2016Review
- Immunomodulatory activity of recombinant Ricin toxin binding Subunit B (RTB).International journal of molecular sciences · 2013Article
- Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- The clinical course of acute pancreatitis and the inflammatory mediators that drive it.International journal of inflammation · 2012Article
- Endotoxin and cancer.Environmental health perspectives · 2009Review
- Targeting TNF-alpha receptors for neurotherapeutics.Trends in neurosciences · 2008Article
- Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence.Biological chemistry · 2008Review
- Cholinergic modulation of inflammation.International journal of clinical and experimental medicine · 2008Article
- Immunomodulatory activity of acidic polysaccharides isolated from Tanacetum vulgare L.International immunopharmacology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As indicated by its name, tumor necrosis factor (TNF), cloned in 1985, was originally described as a macrophage-derived endogenous mediator that can induce hemorrhagic necrosis of solid tumors and kill some tumor cell lines in vitro. Unfortunately, its promising use as an anticancer agent was biased by its toxicity, which was clear soon from the first clinical trials with TNF in cancer. Almost at the same time TNF was being developed as an anticancer drug, it became clear that TNF was identical to a mediator responsible for cachexia associated with sepsis, which was termed cachectin. This research led to the finding that TNF is, in fact, the main lethal mediator of sepsis and to the publication of a huge number of articles showing that TNF inhibits the toxic effects of bacterial endotoxins, which are now described as systemic inflammatory response. Although the clinical trials with anti-TNF in sepsis have not been successful thus far, undoubtedly as a result of the complexity of this clinical setting, these studies ultimately led to the identification of TNF as a key inflammatory mediator and to the development of anti-TNF molecules (soluble receptors and antibodies) for important diseases including rheumatoid arthritis and Crohn's disease. On the other side, the mechanisms by which TNF and related molecules induce cell death have been studied in depth, and their knowledge might, in the future, suggest means of improve the therapeutic index of TNF in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.